A phase lb feasibility study of the combination of panobinostat and midostaurin in recipients of allogeneic stem cell transplantation with Flt3-ITD AML
Latest Information Update: 10 Nov 2020
At a glance
- Drugs Midostaurin (Primary) ; Panobinostat (Primary)
- Indications Acute myeloid leukaemia
- Focus Adverse reactions
- Acronyms HOVON 148 AML
- 10 Nov 2020 Status changed from recruiting to discontinued.
- 07 Aug 2018 Status changed from not yet recruiting to recruiting.
- 07 Aug 2018 Planned number of patients changed from 40 to 30.